<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161509">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987895</url>
  </required_header>
  <id_info>
    <org_study_id>AC-061A301</org_study_id>
    <nct_id>NCT01987895</nct_id>
  </id_info>
  <brief_title>Phase 3 Study With Cadazolid in CDAD</brief_title>
  <official_title>AC-061A301, A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Peru: Instituto Nacional de Salud</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with CDAD are randomized and then treated with study drug for 10 days. At the end
      of treatment, cure is assessed; subjects are then followed-up to assess any disease
      recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An interventional study to investigate the efficacy and safety of cadazolid versus
      vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Cure at End of Treatment</measure>
    <time_frame>End of Treatment(10 days after starting study drug) +2days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resolution of Diarrhea AND No additional CDAD treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Cure</measure>
    <time_frame>End of Treatment(10 days after starting study drug) +28-32 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Cure AND No Recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Diarrhea</measure>
    <time_frame>Baseline to End of Treatment(10 days after starting study drug)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time between the first dose of study drug and Resolution of Diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDAD Symptoms</measure>
    <time_frame>Baseline to End of Treamtent(10 days after starting study drug) +2 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to End of Treatment +2days in CDAD Symptoms as measured by the DaySyms Patient Reported Outcome (PRO).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Clostridium Difficile Associated Diarrhea</condition>
  <arm_group>
    <arm_group_label>Cadazolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cadazolid 250 mg bid or matching placebo granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin 125 mg qid or matching placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cadazolid</intervention_name>
    <description>Cadazolid 250 mg or matching placebo oral suspension twice daily.</description>
    <arm_group_label>Cadazolid</arm_group_label>
    <other_name>ACT-179811</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vancomycin</intervention_name>
    <description>Oral vancomycin 125 mg or matching placebo capsules 4 times daily.</description>
    <arm_group_label>Vancomycin</arm_group_label>
    <other_name>vancomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent.

          -  Male or female ≥ 18 years of age. Females of childbearing potential must agree to use
             an adequate and reliable method of contraception.

          -  Subject with a diagnosis of mild-moderate or severe CDAD (first occurrence or first
             recurrence within 3 months) with: Diarrhea: a change in bowel habits with &gt; 3 liquid
             or unformed bowel movements (UBM) within 24 hours prior to randomization, AND
             Positive C. difficile toxin test on a stool sample produced within 72 hours prior to
             randomization.

        Exclusion Criteria:

          -  More than one previous episode of CDAD in the 3-month period prior to randomization.

          -  Evidence of life-threatening or fulminant CDAD.

          -  Likelihood of death within 72 hours from any cause.

          -  History of inflammatory colitides, chronic abdominal pain, or chronic diarrhea.

          -  Antimicrobial treatment active against CDAD administered for &gt; 24 hours except for
             metronidazole treatment failures (MTF)

          -  Known hypersensitivity or contraindication to study drugs, oxazolidinones, or
             quinolones.

          -  Unable or unwilling to comply with all protocol requirements.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul McGovern, MD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>global medical Information</last_name>
    <email>medinfo@actelion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>South Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Southport</city>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Laatzen</city>
        <zip>30880</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Invetigator Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Munchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bucharest</city>
        <zip>080098</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bucharest</city>
        <zip>011461</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Constanta</city>
        <zip>900709</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Lerida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Madrid</city>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile infection</keyword>
  <keyword>Post-antibiotic diarrhea</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
